Friday, May 07, 2021 6:51:57 PM
Vandana Singh
Fri, May 7, 2021, 4:01 AM·1 min read
https://finance.yahoo.com/news/ibio-stock-trading-higher-announcing-110113853.html
[-chart]s.yimg.com/ny/api/res/1.2/BMQcJJ_iXqdVPZ8ddAfLzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://s.yimg.com/uu/api/res/1.2/I8ba99jCRWs8ZEovIM3Olg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/6f9863940e7c16a73e7bc6c0157539d0[/chart]
https://s.yimg.com/uu/api/res/1.2/I8ba99jCRWs8ZEovIM3Olg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/6f9863940e7c16a73e7bc6c0157539d0">https://s.yimg.com/uu/api/res/1.2/I8ba99jCRWs8ZEovIM3Olg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/6f9863940e7c16a73e7bc6c0157539d0" />
iBio Inc (NYSE: IBIO) has provided an update on its IBIO-201 program and reported its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection.
IBIO-201 combines antigens derived from the spike protein ("S protein") fused with iBio's patented LicKM booster molecule
It recently completed IND-enabling toxicology studies. No adverse effects at low or high doses were identified.
The Company also reported on the development of IBIO-202, a subunit vaccine candidate that targets the nucleocapsid protein ("N protein") of SARS-CoV-2.
"In light of the successful global roll-out of COVID-19 vaccines targeting the S protein and the emergence of variant strains of the disease, we decided to focus our efforts on the continued development of IBIO-202 as a differentiated vaccine candidate," said Tom Isett, Chairman, and CEO.
iBio has expressed N protein antigens and initiated intramuscular and intranasal preclinical studies to identify favorable antigen-adjuvant combinations using its plant-based FastPharming System.
Results are expected in early Q1 FY2022.
Price Action: IBIO shares are 30.4% at $1.80 during premarket trading on the last check Friday.
See more from Benzinga
Click here for options trades from Benzinga
Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients
Cigna's Strong Performance Across Businesses Drive Q1 Earnings Beat; Raises 2021 Guidance
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Advertisement
Quote Lookup
Symbol Last Price Change % Change
IBIOiBio, Inc. 1.6100 +0.2300 +16.67%
Symbol Last Price Change % Change
ACCRAccess-Power & Co., Inc. 0.0240 +0.0066 +37.93%
AABBAsia Broadband, Inc. 0.1869 +0.0360 +23.81%
FTOCFTAC Olympus Acquisition Corp. 10.08 0.00 0.00%
GOEVWCanoo Holdings Ltd. 1.9100 +0.1200 +6.70%
AGCUUAltimeter Growth Corp. 12.35 -0.05 -0.40%
TRENDING
1.
Citi Defeat on $500 Million Error Was Wrong, Groups Say
2.
UPDATE 1-AstraZeneca weighs seeking full U.S. approval for COVID shot - WSJ
3.
Hertz Says Travel Demand Returning After 33% Revenue Decline
4.
UPDATE 1-CDC says U.S.-bound air travelers can use some self-administered COVID-19 tests
5.
Khan Academy’s Sal Khan on the future of higher education and why it might include non-traditional methods
Recent IBIO News
- iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases • GlobeNewswire Inc. • 03/27/2024 11:00:00 AM
- iBio Announces $15.0 Million Private Placement • GlobeNewswire Inc. • 03/26/2024 11:35:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:59:30 PM
- iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka • GlobeNewswire Inc. • 02/26/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:55:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:36:09 PM
- iBio Announces Participation in 23rd Annual PepTalk Conference • GlobeNewswire Inc. • 01/16/2024 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/10/2024 06:24:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:30:59 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/04/2024 01:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 12:44:38 PM
- iBio Amends and Extends Maturity of Credit Agreement • GlobeNewswire Inc. • 12/26/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:17:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 02:13:08 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/06/2023 01:59:51 PM
- iBio, Inc. Announces Pricing of $4.5 Million Public Offering • GlobeNewswire Inc. • 12/05/2023 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/05/2023 05:15:18 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/30/2023 01:55:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 01:36:43 PM
- iBio Announces Reverse Stock Split • GlobeNewswire Inc. • 11/27/2023 10:20:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:01:14 PM
- iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific • GlobeNewswire Inc. • 11/01/2023 12:24:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/27/2023 08:29:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/26/2023 12:20:58 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM